Immunosuppression without calcineurin inhibitors and with the use of everolimus (Certican) in HCV-infected liver transplant patients.

Trial Profile

Immunosuppression without calcineurin inhibitors and with the use of everolimus (Certican) in HCV-infected liver transplant patients.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs Everolimus (Primary) ; Basiliximab; Corticosteroids; Tacrolimus
  • Indications Liver transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Sep 2011 Results presented at the 15th Congress of the European Society for Organ Transplantation.
    • 26 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top